Cargando…

Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection

The expression of the Adenovirus serotype 5 (Ad5) E1A oncogene sensitizes tumor cells to natural killer (NK) cell–mediated killing and tumor rejection in vivo. These effects are dependent on the ability of E1A to bind the transcriptional coadaptor protein p300. To test the hypothesis that E1A up-reg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Routes, John M., Ryan, Sharon, Morris, Kristin, Takaki, Rayna, Cerwenka, Adelheid, Lanier, Lewis L.
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2005
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213342/ https://www.ncbi.nlm.nih.gov/pubmed/16314433 http://dx.doi.org/10.1084/jem.20050240

Ejemplares similares

Adenovirus serotype 5 E1A expressing tumor cells elicit a tumor-specific CD8+ T cell response independent of NKG2D
por: Korrer, Michael J., et al.
Publicado: (2015)

The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease
por: Stojanovic, Ana, et al.
Publicado: (2018)

New twist on the regulation of NKG2D ligand expression
por: Cerwenka, Adelheid
Publicado: (2009)

New twist on the regulation of NKG2D ligand expression
por: Cerwenka, Adelheid
Publicado: (2009)

New prospects on the NKG2D/NKG2DL system for oncology
por: Ullrich, Evelyn, et al.
Publicado: (2013)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Schlegel, Patrick, et al.
Publicado: (2015)

NK Cells Under Hypoxia: The Two Faces of Vascularization in Tumor and Pregnancy
por: Garcés-Lázaro, Irene, et al.
Publicado: (2022)

Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
por: Ni, Jing, et al.
Publicado: (2012)

Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors
por: Pahl, Jens H. W., et al.
Publicado: (2018)

A Role for NKG2D in NK Cell–Mediated Resistance to Poxvirus Disease
por: Fang, Min, et al.
Publicado: (2008)

Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids
por: Giannattasio, Ariane, et al.
Publicado: (2015)

HMGB1: The metabolic weapon in the arsenal of NK cells
por: Cerwenka, Adelheid, et al.
Publicado: (2016)

Toward the next generation of NK cell-based adoptive cancer immunotherapy
por: Ni, Jing, et al.
Publicado: (2013)

Bone Marrow Allograft Rejection Mediated by a Novel Murine NK Receptor, NKG2I
por: Koike, Junzo, et al.
Publicado: (2004)

Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection
por: Lehner, Manfred, et al.
Publicado: (2012)

Cytotoxicity of CD56(bright) NK Cells towards Autologous Activated CD4(+) T Cells Is Mediated through NKG2D, LFA-1 and TRAIL and Dampened via CD94/NKG2A
por: Nielsen, Natasja, et al.
Publicado: (2012)

Chronic In Vivo Interaction of Dendritic Cells Expressing the Ligand Rae-1ε with NK Cells Impacts NKG2D Expression and Function
por: Morvan, Maelig G., et al.
Publicado: (2017)

The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells
por: Kaulfuss, Meike, et al.
Publicado: (2023)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
por: Di Modica, Martina, et al.
Publicado: (2015)

Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ
por: Chen, Xingmeng, et al.
Publicado: (2019)

GSK-3α Inhibition in Drug-Resistant CML Cells Promotes Susceptibility to NK Cell-Mediated Lysis in an NKG2D- and NKp30-Dependent Manner
por: Kim, Nayoung, et al.
Publicado: (2021)

NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
por: Murad, Shafiq, et al.
Publicado: (2022)

Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma
por: Niu, Chao, et al.
Publicado: (2016)

Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality
por: Khaleafi, Raghad, et al.
Publicado: (2023)

Tumor-Derived Soluble MICA Obstructs the NKG2D Pathway to Restrain NK Cytotoxicity
por: Luo, Qizhi, et al.
Publicado: (2020)

Macrophages Help NK Cells to Attack Tumor Cells by Stimulatory NKG2D Ligand but Protect Themselves from NK Killing by Inhibitory Ligand Qa-1
por: Zhou, Zhixia, et al.
Publicado: (2012)

Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk
por: Chinnery, Fay, et al.
Publicado: (2012)

Potential of the NKG2D/NKG2DL Axis in NK Cell-Mediated Clearance of the HIV-1 Reservoir
por: Desimio, Maria G., et al.
Publicado: (2019)

CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition
por: Liu, Meng, et al.
Publicado: (2022)

Innate-like NKp30(+)CD8(+) T cells armed with TCR/CAR target tumor heterogeneity
por: Correia, Margareta P., et al.
Publicado: (2021)

Inhibitory NKG2A(+) and absent activating NKG2C(+) NK cell responses are associated with the development of EBV(+) lymphomas
por: Vietzen, Hannes, et al.
Publicado: (2023)

Polyclonal Expansion of NKG2C(+) NK Cells in TAP-Deficient Patients
por: Béziat, Vivien, et al.
Publicado: (2015)

NKG2A is a NK cell exhaustion checkpoint for HCV persistence
por: Zhang, Chao, et al.
Publicado: (2019)

High Metabolic Function and Resilience of NKG2A-Educated NK Cells
por: Highton, Andrew J., et al.
Publicado: (2020)

Responsiveness to Influenza Vaccination Correlates with NKG2C-Expression on NK Cells
por: Riese, Peggy, et al.
Publicado: (2020)

Dissection of the NKG2C NK cell response against Puumala Orthohantavirus
por: Vietzen, Hannes, et al.
Publicado: (2021)

Spontaneous Tumor Lysis Syndrome in T-Cell Leukemia
por: Faheem, Beenish, et al.
Publicado: (2020)

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
por: Koch, Christine, et al.
Publicado: (2017)

CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells
por: Chen, Zhangguo, et al.
Publicado: (2011)

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
por: André, Pascale, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u8tb7ml2rrof2521uk1h0jvi2c